DBV Technologies (DBVT)
(Delayed Data from NSDQ)
$0.97 USD
+0.02 (2.11%)
Updated Aug 2, 2024 02:30 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
DBV Technologies S.A. [DBVT]
Reports for Purchase
Showing records 21 - 40 ( 48 total )
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
An Opportunity That Could Stick - FDA Clarity Outlines Next Steps for Viaskin
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
FDA CRL for Viaskin Peanut Taps the Brakes, Offers Opportunity to Patch Remaining Issues; PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Corporate Restructuring a Proactive Step, Amid Forthcoming BLA Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
BLA Questions on Patch Adhesion Necessitate Additional Information for FDA; A Hurdle That Viaskin Can Surmount
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Progress for Viaskin Immunotherapy With AdCom Expected May 2020, Potential Launch 2H20; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Positive Viaskin Phase 3 Extension Study Topline Data Supportive of 2H20 PDUFA Traction; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Confidence in Viaskin Peanut Patch Informed by Proprietary 100-Physician Survey; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Viaskin BLA Acceptance Marks Step Forward in Peanut Allergy; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
FDA AdCom Provides Insight Into Peanut Allergy Treatment and Safety Considerations.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
BLA Resubmission for Viaskin Peanut on Horizon, Anticipated in 3Q19; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Believe a Successful BLA Resubmission Can Be a Meaningful Catalyst; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Path Towards Filing Emerges; First Step Towards a Renewed Focus on Fundamentals, We Believe
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Additional Uncertainty Injected into Equation; Maintain Buy but Lower PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
With the Trial Complete, It Is Now Up to the Regulators, Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Believe Pipeline in a Program Thesis is Emerging Following Viaskin Milk Data; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Peanut Allergy and HAE Updates from ACAAI Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Confidence Shaken; But Not Stirred; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Week Ahead - Week of September 18, 2017
Provider: WEDBUSH SECURITIES INC.
Company: DBV Technologies S.A.
Industry: Medical - Biomedical and Genetics
Focus on Peanut Allergy: Takeaways From Our KOL Dinner
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A